Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, prescribed for the treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with cardiovascular disease. It is important to note that Ozempic is not specifically indicated for weight loss, but weight loss can be a side effect of its use [1].

Regarding snacking habits, a study published in the journal Diabetes, Obesity and Metabolism found that semaglutide treatment resulted in a significant reduction in appetite and food cravings compared to a placebo [2]. This reduction in appetite and food cravings may lead to a decrease in snacking, as individuals feel less hungry between meals.

Moreover, a review published in the journal Endocrine Connections highlighted that GLP-1 receptor agonists, such as Ozempic, can lead to a decrease in overall food intake and a reduction in body weight [3]. This decrease in food intake could be attributed to a decrease in snacking habits, as individuals may feel less inclined to eat between meals due to a decrease in appetite and an improvement in glucose control.

In summary, Ozempic may impact snacking habits due to its ability to reduce appetite and food cravings, leading to a decrease in overall food intake and body weight. However, it is important to note that Ozempic is primarily prescribed for the treatment of type 2 diabetes and cardiovascular disease, and any weight loss or changes in snacking habits should be considered a potential side effect rather than the primary goal of treatment.

Sources:
[1] DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/ozempic>
[2] Halford, J. C., Harmer, L. J., Wright, P., Seeley, R. J., & Bloom, S. R. (2018). Effects of semaglutide on appetite, food preference and food intake in overweight and obese subjects. Diabetes, Obesity and Metabolism, 20(2), 387-396.
[3] Wilding, J. P. H., & Batterham, R. L. (2015). Glucagon-like peptide-1 receptor agonists: mechanisms of action, therapeutic potential, and clinical utility. Endocrine Connections, 4(4), R61-R72.